Liminatus Pharma, Inc. Class A Common Stock (LIMN) — Cash Flow-to-Debt Ratio
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a Cash Flow-to-Debt Ratio of -0.69x as of March 2026, meaning its operating cash flow of $-2.02 Million could theoretically repay -1% of its total liabilities ($2.92 Million) in one year. See Liminatus Pharma, Inc. Class A Common St free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Liminatus Pharma, Inc. Class A Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Liminatus Pharma, Inc. Class A Common Stock across 5 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Liminatus Pharma, Inc. Class A Common St.
Annual Cash Flow-to-Debt Ratio for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
Year-by-year debt coverage analysis for Liminatus Pharma, Inc. Class A Common Stock. Check LIMN cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.96x | $-9.96 Million | $10.33 Million | ▼ -480.7% |
| 2024 | -0.17x | $-3.11 Million | $18.70 Million | ▲ +24.5% |
| 2023 | -0.22x | $-3.35 Million | $15.19 Million | ▼ -259.6% |
| 2022 | -0.06x | $-869.00K | $14.19 Million | ▼ -8.6% |
| 2021 | -0.06x | $-1.22 Million | $21.57 Million | — |